GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Insight Molecular Diagnostics Inc (NAS:IMDX) » Definitions » Enterprise Value

IMDX (Insight Molecular Diagnostics) Enterprise Value : $53.96 Mil (As of Jul. 06, 2025) ***


View and export this data going back to 2015. Start your Free Trial

What is Insight Molecular Diagnostics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Insight Molecular Diagnostics's Enterprise Value is $53.96 Mil. Insight Molecular Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-58.11 Mil. Therefore, Insight Molecular Diagnostics's EV-to-EBIT ratio for today is -0.93.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Insight Molecular Diagnostics's Enterprise Value is $53.96 Mil. Insight Molecular Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-56.39 Mil. Therefore, Insight Molecular Diagnostics's EV-to-EBITDA ratio for today is -0.96.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Insight Molecular Diagnostics's Enterprise Value is $53.96 Mil. Insight Molecular Diagnostics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $3.84 Mil. Therefore, Insight Molecular Diagnostics's EV-to-Revenue ratio for today is 14.04.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Insight Molecular Diagnostics's Enterprise Value is $53.96 Mil. Insight Molecular Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-23.54 Mil. Therefore, Insight Molecular Diagnostics's EV-to-FCF ratio for today is -2.29.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Insight Molecular Diagnostics Enterprise Value Historical Data

The historical data trend for Insight Molecular Diagnostics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insight Molecular Diagnostics Enterprise Value Chart

Insight Molecular Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 166.01 171.99 21.19 14.09 36.57

Insight Molecular Diagnostics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.00 33.85 38.74 36.57 59.96

Competitive Comparison of Insight Molecular Diagnostics's Enterprise Value

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Enterprise Value falls into.


;
;

Insight Molecular Diagnostics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Insight Molecular Diagnostics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Insight Molecular Diagnostics's Enterprise Value for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insight Molecular Diagnostics  (NAS:IMDX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Insight Molecular Diagnostics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=53.957/-58.107
=-0.93

Insight Molecular Diagnostics's current Enterprise Value is $53.96 Mil.
Insight Molecular Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.11 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Insight Molecular Diagnostics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=53.957/-56.387
=-0.96

Insight Molecular Diagnostics's current Enterprise Value is $53.96 Mil.
Insight Molecular Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.39 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Insight Molecular Diagnostics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=53.957/3.843
=14.04

Insight Molecular Diagnostics's current Enterprise Value is $53.96 Mil.
Insight Molecular Diagnostics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.84 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Insight Molecular Diagnostics's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=53.957/-23.54
=-2.29

Insight Molecular Diagnostics's current Enterprise Value is $53.96 Mil.
Insight Molecular Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insight Molecular Diagnostics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Insight Molecular Diagnostics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Insight Molecular Diagnostics Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno director C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011